MRK Stock Forecast: Merck & Co., Inc. Price Predictions for 2026-2027
The 28 Wall Street analysts covering Merck & Co., Inc. hold a median 12-month price target of $165 — +23.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 86 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Merck & Co., Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (100): The share price has been relatively steady.
Growth (35): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
MRK stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MRK, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +23.4% from it.
Of the 20 most recent actions, 17 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Nov 2026 | Cantor Fitzgerald | Maintains | Neutral | $145 → $155 |
| 2 Nov 2026 | Freedom Broker | Maintains | Hold | $125 → $140 |
| 30 Oct 2026 | Guggenheim | Maintains | Buy | $170 → $171 |
| 30 Oct 2026 | JP Morgan | Maintains | Overweight | $165 → $175 |
| 30 Oct 2026 | RBC Capital | Maintains | Sector Perform | $145 → $140 |
| 26 Oct 2026 | Barclays | Maintains | Overweight | $150 → $180 |
| 12 Oct 2026 | Citigroup | Maintains | Neutral | $125 → $145 |
| 12 Oct 2026 | RBC Capital | Maintains | Sector Perform | $150 → $145 |
| 8 Oct 2026 | Cantor Fitzgerald | Maintains | Neutral | $120 → $145 |
| 7 Oct 2026 | Morgan Stanley | Maintains | Overweight | $179 → $177 |
| 5 Oct 2026 | JP Morgan | Maintains | Overweight | $150 → $165 |
| 29 Sept 2026 | Scotiabank | Maintains | Sector Outperform | $155 → $180 |
| 10 Sept 2026 | HSBC | Maintains | Buy | $150 → $172 |
| 9 Sept 2026 | Leerink Partners | Maintains | Outperform | $127 → $161 |
| 8 Sept 2026 | Guggenheim | Maintains | Buy | $146 → $170 |
| 4 Sept 2026 | Wells Fargo | Maintains | Overweight | $150 → $170 |
| 25 Aug 2026 | Argus Research | Maintains | Buy | $145 → $170 |
| 25 Aug 2026 | Wolfe Research | Maintains | Outperform | $155 → $180 |
| 21 Aug 2026 | Goldman Sachs | Maintains | Buy | $140 → $160 |
| 20 Aug 2026 | BMO Capital | Maintains | Outperform | $142 → $170 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MRK.
This page is one stock. Monday covers all of them.
MRK appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
MRK vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Merck & Co., Inc. returned +44.9% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
MRK analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 135.1×
- Price / sales
- 4.9×
- Price / book
- 7.3×
- EV / EBITDA
- 12.7×
Cheaper than 6% of US stocks
Cheaper than 21% of US stocks
Cheaper than 11% of US stocks
Cheaper than 43% of US stocks
- Revenue growth (YoY)
- 4.7%
- Earnings growth (YoY)
- −12.4%
- Gross margin
- 73.5%
- Operating margin
- 35.2%
- Net margin
- 3.6%
Higher than 40% of US stocks
Higher than 24% of US stocks
Higher than 86% of US stocks
Higher than 90% of US stocks
Higher than 53% of US stocks
- Return on equity
- 5.1%
- Return on assets
- 11.3%
- Dividend yield
- 2.5%
Higher than 52% of US stocks
Higher than 94% of US stocks
Higher than 53% of US dividend payers
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Merck & Co., Inc. has a market value of $329.7B and an enterprise value of $374.0B.
Revenue in the twelve months to 30 June 2026: $66.6B. The latest quarter grew 5.1% year on year.
Net income over the same four quarters: $3.2B, a 4.8% net margin.
Diluted earnings per share, trailing twelve months: $1.25.
Free cash flow in the twelve months to 30 June 2026: $16.1B, after $3.9B of capital spending.
Merck & Co., Inc. spent $4.2B on share buybacks and $8.3B on dividends in the twelve months to 30 June 2026.
Trailing P/E: 135.1×; forward P/E: 14.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.54%, paying out 343% of earnings.
Merck & Co., Inc. employs 73,000 people — $912K of revenue per employee.
Data provided by Twelve Data
MRK and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at MRK’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Merck & Co., Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about MRK
What is the MRK stock price forecast for 2026-2027?
The 28 Wall Street analysts covering Merck & Co., Inc. have a median 12-month price target of $165, with estimates ranging from $105 to $186. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MRK stock a buy right now?
Of the 28 analysts covering Merck & Co., Inc., 19 rate it a Buy, 9 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Merck & Co., Inc. 86 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MRK?
As at 21 Nov 2026, Merck & Co., Inc. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).
Will MRK stock go up?
No one can know that. What the data says: the median 12-month target from 28 analysts implies +23.4% from the last close, and Ticker Nerd's factor model ranks Merck & Co., Inc. 86 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MRK stock forecast for 2030?
No analyst covering Merck & Co., Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MRK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $105 to $186 over the next 12 months.
How has MRK stock performed over the past year?
Merck & Co., Inc. returned +44.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Merck & Co., Inc. do?
Merck & Co., Inc. is a global healthcare company focused on developing, manufacturing, and delivering prescription medicines, vaccines, and biologic therapies. Its human health portfolio addresses major disease areas including oncology, infectious diseases, cardiology, immunology, and hospital-based care.
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare company focused on developing, manufacturing, and delivering prescription medicines, vaccines, and biologic therapies. Its human health portfolio addresses major disease areas including oncology, infectious diseases, cardiology, immunology, and hospital-based care. The company also operates an animal health business that provides veterinary pharmaceuticals, vaccines, and technology-supported solutions for livestock, companion animals, and aquaculture. Merck & Co., Inc. serves healthcare professionals, hospitals, governments, pharmacies, patients, veterinarians, farmers, and animal owners across international markets. Through research, clinical development, manufacturing, regulatory expertise, and commercial distribution, the company supports the prevention, diagnosis, and treatment of disease. Its role in the pharmaceutical market spans innovative medicines, vaccines, and specialty therapies, while its animal health segment contributes to disease prevention and productivity across food-animal and pet-care industries. Merck & Co., Inc. is headquartered in Rahway, New Jersey, and operates as a major participant in the global healthcare sector.
CEO Mr. Robert M. Davis J.D. · 73,000 employees · United States · https://www.merck.com